Deputy Transport Minister Michael Keenan, one of the key players behind the federal government’s decision to bar unvaccinated Canadians from flying or boarding a train, will testify before the Public Order Emergency Commission.
As first exposed by True North’s Cosmin Dzsurdzsa on Tuesday, Keenan is one of eight government bureaucrats lobbied by Pfizer six days after some of the world’s most restrictive COVID-19 mandates were implemented.
A lobbying Monthly Communication Report shows that Pfizer Canada ULC representatives met with federal officials representing some of Canada’s top departments on November 5, 2021.
The list includes: Health Canada Associate Deputy Minister Heather Jeffrey, Privy Council Office Deputy Minister Thao Pham, Federal Lead onf Proof of Vaccine Credentials and Associate Deputy Minister at Immigration, Refugees and Citizenship Canada Scott Jones, Associate Deputy Innovation Minister Paul Thompson, Executive Vice President of the Canadian Border Services Agency Ted Gallivan, Executive Vice President of the Public Health Agency of Canada Kathy Thompson and Vice-President of the Canada Border Services Agency Denis Vinette.
Travel restrictions were implemented on Oct. 30, 2021.
“Conservatives MUST press Mr. Keenan on the above meeting when he testifies, otherwise this entire thing is a sham. We need to once and for all get to the bottom of how much of a role Pfizer played directly or indirectly in instituting draconian mandates,” Dzsurdzsa wrote in a follow-up tweet.
The Deputy will testify before the Public Order Emergency Commission which begins Thursday alongside over 60 other witnesses, including Prime Minister Justin Trudeau and other members of the Liberal cabinet.
Officials will be questioned on whether the use of the Emergencies Act was reasonable to crush anti-mandate Freedom Convoy protests last winter.
The Commission comes on the heels of a stunning new revelation by a top Pfizer executive that the COVID-19 vaccine was never tested for transmission.
“Regarding the question around, did we know about stopping immunization before it entered the market? No,” said Pfizer president of international development markets Janine Small.
“These, um, you know, we had to really move at the speed of science to really understand what is taking place in the market. And from that point of view, we had to do everything at risk.”